<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070355</url>
  </required_header>
  <id_info>
    <org_study_id>GA09/9094</org_study_id>
    <secondary_id>2009-015903-22</secondary_id>
    <nct_id>NCT01070355</nct_id>
  </id_info>
  <brief_title>Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases</brief_title>
  <acronym>EMT</acronym>
  <official_title>The Effects of Eicosapentaenoic Acid (EPA) on Biomarkers of Growth and Vascularity in Human Colorectal Cancer Liver Metastases (The EPA for Metastasis Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eicosapentaenoic acid (EPA) is a naturally occuring omega-3 polyunsaturated fatty acid found
      in oily fish. EPA has anti-colorectal (bowel) cancer activity in experimental models. This
      trial will test whether EPA reduces markers of tumour growth, and is safe and well
      tolerated,in patients with colorectal cancer liver metastases awaiting surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomised, placebo-controlled trial of eicosapentaenoic acid (EPA), in the
      free fatty acid form, 2g daily in patients who will undergo liver resection surgery for
      colorectal cancer liver metastases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Ki67 cancer cell proliferation index</measure>
    <time_frame>at surgery 2-6 weeks after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological neo-CK18 cancer cell apoptosis index</measure>
    <time_frame>at surgery 2-6 weeks after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological tumour CD31-positive cell microvessel density</measure>
    <time_frame>at surgery 2-6 weeks after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of EPA treatment</measure>
    <time_frame>Every 2 weeks whilst patient is taking study medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastatic tissue and healthy liver tissue fatty acid composition and prostaglandin levels</measure>
    <time_frame>at surgery 2-6 weeks after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma markers of prostaglandin metabolism</measure>
    <time_frame>1. Baseline 2. after approx 4 weeks of study medication (immediately prior to surgery). 3. Six weeks after liver resection (no study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>1. Baseline 2. after approx 4 weeks of study medication (immediately prior to surgery). 3. Six weeks after liver resection (no study medication)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary markers of prostaglandin metabolism</measure>
    <time_frame>1. Baseline 2. after 2 weeks of study medication 3. after approx 4 weeks of study medication (immediately prior to surgery). 4. Six weeks after liver resection (no study medication)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eicosapentaenoic acid free fatty acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2g daily (2 x 500mg capsules twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eicosapentaenoic acid free fatty acid</intervention_name>
    <description>An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.</description>
    <arm_group_label>Eicosapentaenoic acid free fatty acid</arm_group_label>
    <other_name>ALFA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules taken twice daily for 2-6 weeks before liver resection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Either sex

          -  Liver resection deemed clinically appropriate for management of metastatic colorectal
             cancer

          -  Duration between decision to perform liver resection and surgery greater than 2 weeks

          -  Ability to give written informed consent and follow study protocol

          -  Telephone contact possible

        Exclusion Criteria:

          -  Neo-adjuvant chemotherapy for colorectal cancer (CRC) liver metastasis

          -  Chemotherapy for any cancer in the previous 3 months

          -  Known bleeding diathesis or anticoagulation therapy

          -  Fish or seafood allergy

          -  Use of fish oil supplements (eg. cod liver oil) and unwilling to stop for the duration
             of the study

          -  Pregnancy

          -  Non-aspirin non-steroidal anti-inflammatory (NSAID) or corticosteroid use

          -  Renal impairment (serum creatinine &gt;150)

          -  Active inflammatory disease (e.g. Inflammatory Bowel Disease, Rheumatoid Arthritis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Hull, PhD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Institute of Molecular Medicine, University of Leeds</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Institute of Molecular Medicine, St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>October 20, 2011</last_update_submitted>
  <last_update_submitted_qc>October 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Mark Hull</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Fish Oils</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Eicosapentaenoic Acid</keyword>
  <keyword>Liver Metastases</keyword>
  <keyword>Randomised Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

